IO in EC: Rationales

CE / CME

Rationales for Using Immunotherapy-Based Regimens in Advanced Endometrial Cancer

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 23, 2023

Expiration: October 22, 2024

Lauren Prescott
Lauren Prescott, MD, MPH
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1 2
Course Completed

References

  1. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. seer.cancer.gov/statfacts/html/corp.html. Accessed October 11, 2023.
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: uterine neoplasms.v.1.2024. nccn.org. Accessed October 11, 2023. 
  4. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006:95(suppl 1):S105-S143.
  5. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nat Genet. 2013;497:67-73.
  6. MacKay HJ, Levine DA, Bae-Jump VL, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 2017;8:84579-84594. 
  7. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069-1086.
  8. Vanderstraeten A, Luyten C, Verbist G, et al. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63:545-557.
  9. Herzog TJ, Arguello D, Reddy SK, et al. PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy. Presented at: 2015 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 28-31, 2015. Abstract 509.
  10. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends Cancer. 2023;9:828-839. 
  11. Rizzo A. Immune checkpoint inhibitors and mismatch repair status in advanced endometrial cancer: elective affinities. J Clin Med. 2022;11:3912. 
  12. Cao W, Ma X, Fischer JV, et al. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res. 2021;9:49.
  13. Tinker AV, Dhani NC, Ghatage P, et al. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer. Ther Adv Med Oncol. 2023;15:17588359231157633.
  14. Margul D, Yu C, AlHilli MM. Tumor immune microenvironment in gynecologic cancers. Cancers. 2023;15:3849.
  15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: melanoma: cutaneous. v.2.2023. nccn.org. Accessed October 11, 2023.
  16. Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94-101.
  17. Onji H, Murai J. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes. Cancer Sci. 2022;113:2943-2951.
  18. Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
  19. Lenvatinib [prescribing information]. Nutley, NJ: Eisai Inc; 2022.
  20. Song Y, Fu Y, Xie Q, et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol. 2020;11:1956. 
  21. Dostarlimab [prescribing information]. Collegeville, PA: GlaxoSmithKline LLC; 2023.
  22. Mirza MR, Coleman RL, Hanker L, et al. ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: a phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 821TiP.
  23. Zhu DL, Tuo XM, Rong Y, et al. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. J Cancer. 2020;11:7264-7275.
  24. Futibatinib [prescribing information]. Princeton, NJ: Taiho Oncology, Inc; 2022.
  25. Passarelli A, Pisano C, Cecere SC, et al. Targeting immunometabolism mediated by the IDO1 pathway: a new mechanism of immune resistance in endometrial cancer. Front Immunol. 2022:13:953115.
  26. Le Naour J, Galluzzi L, Zitvogel L, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2020;9:1777625.
  27. Pemigatinib [prescribing information]. Wilmington, DE: Incyte Corp; 2022.
  28. Karpel HC, Powell SS, Pothuri B. Antibody-drug conjugates in gynecologic cancer. Am Soc Clin Oncol Educ Book. 2023;43:e390772.
  29. Li BT, Pegram MD, Lee KW, et al. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 2538.
  30. Buza N. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med. 2020;145:687-691.
  31. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26:3928-3935.
  32. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA300.
  33. Bignotti E, Ravaggi A, Romani C, et al. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with Hrs7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer. 2011;21:1613-1621.
  34. Senol S, Ceyran AB, Aydin A, et al. Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. Int J Clin Exp Pathol. 2015;8:5633-5641.
  35. Mirvetuximab soravtansine [prescribing information]. Waltham, MA: ImmunoGen, Inc; 2022.
  36. Khattak A, Weber JS, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA9503.
  37. Levinson K, Dorigo O, Rubin K, et al. Immunotherapy in gynecologic cancers: what we know now and where we are headed. Am Soc Clin Oncol Educ Book. 2019;39:e126-e140.
  38. Khan AN, Asija S, Pendhari J, et al. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? Eur J Haematol. 2023;[Epub ahead of print].
  39. US Food and Drug Administration. Bispecific antibodies: an area of research and clinical applications. fda.gov/drugs/news-events-human-drugs/bispecific-antibodies-area-research-and-clinical-applications. Accessed October 11, 2023.